Supriya Lifescience share news, announcements and annual reports
NSE: SUPRIYABSE: 543434Pharmaceuticals & BiotechnologySmall Cap
Supriya Lifescience Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2021 · Issue price ₹274
Last close ₹847.30down ₹22.00 (2.53%)BSE ₹846.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹869.30.
30 Oct: open ₹869.30, high ₹880.45, low ₹841.80
52-week range of traded prices to 30 Oct 2026
₹545.50Low, 24 Mar 2026₹1,085.00High, 1 Jun 2026
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹6,819 Cr733rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.38
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.69
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 92,05249.3% delivered
Supriya Lifescience disputes and clarifications
31 filed, newest first.
Sep 2026
2 Sep · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
Mar 2026
10 Mar · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted. The response of the Company is awaited.
Feb 2026
Jan 2026
13 Jan · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Sep 2025
11 Sep · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Jul 2025
Jun 2025
26 Jun · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Nov 2024
13 Nov · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Aug 2024
22 Aug · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Jun 2024
20 Jun · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Mar-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Mar 2024
13 Mar · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Dec-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Dec 2023
14 Dec · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Sep-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Aug 2023
4 Aug · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 30-Jun-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Jun 2023
16 Jun · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Feb 2023
23 Feb · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Dec-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Sep 2022
7 Sep · Legal
Exchange has sought clarification from Supriya Lifescience Limited with respect to Financial Results dated 12-Aug-2022 for the period Jun, 2022On the basis of aforesaid disclosure, the Listed entity is required to clarify the following:1. Standalone: Segment Reporting - Not foundThe response of the company is awaited
May 2022
26 May · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Mar-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Mar 2022
11 Mar · Legal
Exchange has sought clarification from Supriya Lifescience Limited for the quarter ended 31-Dec-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.